Drug intelligence / Profile preview

Akkermansia muciniphila + infliximab

Development stage: Unknown
Lead developer: Chinese Medical Association
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral, Intravenous

Overview

Akkermansia muciniphila + infliximab is a combination therapy being evaluated for the treatment of active Crohn's disease. It consists of infliximab, a chimeric monoclonal antibody that targets and neutralizes tumor necrosis factor-alpha (TNF-alpha) to reduce systemic and local inflammation, and Akkermansia muciniphila, a next-generation probiotic bacterium. A. muciniphila is a mucin-degrading anaerobe that naturally inhabits the human gut and is associated with improved intestinal barrier integrity and immune homeostasis. The combination aims to leverage the potent anti-inflammatory effects of TNF-alpha inhibition alongside the microbiome-modulating and mucosal-healing properties of the probiotic to achieve superior clinical outcomes, specifically complete mucosal healing, compared to infliximab monotherapy. This specific regimen is currently being investigated in a Phase 4 trial sponsored by the Chinese Medical Association.

Other names: Akkermansia muciniphila and infliximab combination therapyAkkermansia muciniphila + Infliximab

Targets

TNFA (Tumor necrosis factor alpha (soluble))TLR2 (Toll-like Receptor 2)

Beyond the preview

Go deeper on Akkermansia muciniphila + infliximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akkermansia muciniphila + infliximab.

Explore the full profile